Jefferies stays Buy on Protagonist Therapeutics (PTGX) amid JNJ's bullish tone on Icotyde

April 14, 2026 3:13 PM

Jefferies analyst Roger Song reiterated a Buy rating and $121.00 price target on Protagonist Therapeutics (NASDAQ: PTGX)The analyst commented, "JNJ ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found